John McKearn

John McKearn

Chairman presso Arch Oncology, Inc.

Patrimonio netto: 160 075 $ in data 29/02/2024

70 anni
Health Technology
Consumer Services
Finance

Profilo

John P.
McKearn
occupies the position of Chairman for Arch Oncology, Inc. and Managing Director at RiverVest Venture Management LLC.
Dr. McKearn is also on the board of 7 other companies.
In his past career Dr. McKearn was President & Chief Executive Officer for Kalypsys, Inc., Head-Discovery Research at Searle & Co., Inc., Senior Scientist at E.I.
du Pont de Nemours & Co., Head-Discovery Research at Pharmacia Corp., Head-Discovery Research at G.D.
Searle LLC, Research Associate at Washington University in St. Louis and Member of Basel Institute for Immunology.
He received a doctorate from The University of Chicago and an undergraduate degree from Northern Illinois University.John McKearn, PhD, is a Managing Director at RiverVest Venture Partners.
John has almost 30 years’ experience as a successful “drug hunter and developer” in both large and small biopharma, including a decade in small-cap and venture-backed companies.
Prior to joining RiverVest, he was president and CEO of Kalypsys, Inc., and has served on the boards of IDM Pharma, Inc. (acquired by Takeda), Epimmune and Keel Pharmaceuticals, Inc. John worked as a scientist with Searle / Pharmacia, from 1987-2003, including head of discovery research from 1997-2003.
Through his efforts, John helped establish the groundwork for new studies that led to the commercialization of several major products, including DayPro, Arthrotec, and most notably, Celebrex, one of the leading pharmaceuticals to treat arthritis.
Prior to 1987, John was a senior scientist at E.I.
DuPont de Nemours and Company; a member of the Basel Institute for Immunology in Basel, Switzerland; and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis.
John completed his PhD in immunology from the University of Chicago and his BS in biology from Northern Illinois University.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
16/01/2024 108 159 ( 0.12% ) 160 075 $ 29/02/2024

Posizioni attive di John McKearn

SocietàPosizioneInizio
Private Equity Investor 01/04/2008
Chairman 16/08/2016
Director/Board Member -
Director/Board Member -
Director/Board Member 25/08/2022
OxaluRx, Inc. Director/Board Member -
Director/Board Member -
Private Equity Investor -
Tutte le posizioni attive di John McKearn

Precedenti posizioni note di John McKearn

SocietàPosizioneFine
ALLAKOS INC. Director/Board Member 25/05/2023
░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░ ░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
░░░ ░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di John McKearn

Formazione di John McKearn

The University of Chicago Doctorate Degree
Northern Illinois University Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di John McKearn

Relazioni

100 +

Relazioni di 1° grado

25

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa1
ALLAKOS INC.

Health Technology

Aziende private20

Process Industries

Epimmune, Inc.

Health Technology

Health Technology

Keel Pharmaceuticals, Inc.

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Finance

Electronic Technology

Finance

Health Technology

G.D. Searle LLC

Commercial Services

Health Technology

Health Technology

Technology Services

OxaluRx, Inc.

Miscellaneous

Commercial Services

Vedi le connessioni aziendali
  1. Borsa
  2. Insiders
  3. John McKearn